---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-25-000023"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T01:57:58.953894+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance

## Summary
- Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).
- Net loss $14.4M ($0.36 per share) vs $13.7M ($0.36) in Q1 2024; adjusted EBITDA loss $8.5M vs $8.0M.
- Reaffirms FY2025 revenue guidance $96M-$98M; expects gross margin ~74% and OpEx $133M-$135M.
- U.S. DOJ declined to intervene in case against Pulmonx and closed the civil investigative demand.
- Amended CIBC loan to extend interest-only period through October 2027; cash & securities $88.7M.

## SEC filing metadata
- accession: 0001127537-25-000023
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/0001127537-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/lung-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-25-000023
- JSON: https://secwatch.observer/filing/0001127537-25-000023.json
- Plain text: https://secwatch.observer/filing/0001127537-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.